C-peptide, a 31–amino acid peptide originally regarded as an inert by‐product of insulin synthesis, is emerging as a key modulator of diabetic complications. Secreted in equimolar amounts with insulin ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with new-onset type 1 diabetes receiving ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Baricitinib preserved C-peptide levels and lowered ...
This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. SAN ...
Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression. 14-Month Follow-up Data Sho ...
Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...
A two-step screening protocol that combines clinical risk assessment with biomarker testing can more effectively identify which patients with Type 2 diabetes need medication to prevent heart failure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results